Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
- CANbridge to lead development and commercialization in China; expands rare disease pipeline - Mirum is entitled to receive up...






